Dr. Andrew Luster, chief of rheumatology at Massachusetts General Hospital and professor at Harvard Medical School, distinguishes acute from chronic inflammation with a key metric: C-reactive protein (CRP) above 3.0 mg/L correlates with a 45% increased cardiovascular risk per the JUPITER trial (n=17,802). Inflammation is a survival mechanism. When you cut your finger, the inflammatory cascade recruits immune cells, increases blood flow, and initiates repair. Chronic inflammation is low-grade, systemic, and persistent, and it has been implicated in cardiovascular disease, type 2 diabetes, neurodegeneration, and multiple cancers. Dr. Paul Ridker, a cardiologist at Brigham and Women's Hospital who led the landmark CANTOS trial, demonstrated that reducing inflammation (via IL-1β inhibition) independently lowered cardiovascular events — proof that inflammation is not merely a marker but a driver of disease.
The primary biomarker for systemic inflammation is high-sensitivity C-reactive protein (hs-CRP). Levels below 1.0 mg/L indicate low cardiovascular risk; above 3.0 mg/L indicates elevated risk. But CRP is nonspecific: it rises with infection, injury, obesity, and even poor sleep.
Visceral adipose tissue is the most significant modifiable driver of chronic inflammation. Fat cells are not inert storage; visceral fat actively secretes inflammatory cytokines (IL-6, TNF-alpha) that enter systemic circulation. A waist measurement above 40 inches in men or 35 inches in women correlates with measurably higher inflammatory markers.
The gut microbiome modulates systemic inflammation through intestinal permeability. Dr. Alessio Fasano, professor of pediatrics at Harvard Medical School, discovered zonulin — the protein that regulates tight junctions between intestinal epithelial cells. When the epithelial barrier is compromised, bacterial endotoxins (lipopolysaccharides) enter the bloodstream and trigger immune activation. This mechanism, called metabolic endotoxemia, was first characterized by Dr. Rémy Burcelin at INSERM Toulouse (Diabetes 2007, n=mice) and is increasingly supported in human studies.
Sleep deprivation raises inflammatory markers independently of other factors. Dr. Michael Irwin, professor of psychiatry at UCLA and director of the Cousins Center for Psychoneuroimmunology, led a Sleep Medicine Reviews meta-analysis (k=72, n=50,000+) showing that both short sleep (under 6 hours) and poor sleep quality significantly increase CRP and IL-6. The effect is bidirectional: inflammation disrupts sleep architecture, and disrupted sleep increases inflammation — a vicious cycle that Dr. Irwin describes as the "inflammatory-sleep axis."
Dietary patterns show consistent anti-inflammatory effects in randomized trials. Mediterranean dietary patterns reduce CRP by 20-30% in trials lasting 3-12 months. The active components appear to be omega-3 fatty acids, polyphenols, and fiber, rather than any single food.